COMPARE · Data as of August 21, 2026
INDV vs NBIX
Verdict: Side-by-side breakdown using the Bull Rankings model. INDV scored 63.0, NBIX scored 88.0 — NBIX leads.
Compare another set
INDV
Indivior Pharmaceuticals, Inc.
63
$36.87 · $4.4B
fundamentals as of
Score gap
25.0
NBIX leads
NBIX
Neurocrine Biosciences, Inc.
88
$152.57 · $15.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthNBIX+34.4%
- Highest qualityNBIX81 / 100
- Largest discount to fair valueNBIX-11%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
INDV
stronger →← stronger
NBIX
50
Qualityreturns · margins · balance sheet
81
87
Growthrevenue & earnings expansion
96
57
Valuevaluation vs sector peers
88
NBIX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
INDV
NBIX
-$111mF
FCF
$870mC+
+13.5%B+
Rev
+34.4%A
—
D/E
0.12B+
3.3xB+
P/S
—
1.26B
PEG
0.46A
—
P/E
22.3xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
INDV
NBIX
—
Price vs fair valuelower is cheaper
11% below
—
Growth the price implies10-yr FCF · lower = less priced in
~8%/yr
—
1-yr DCF upside
-6%
—
5-yr DCF upside
+13%
—
10-yr DCF upside
+47%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
INDV
Why this score
- Buying back stock
NBIX
Why this score
- Durable high returns
- Diluting shareholders
The companies
INDVIndivior Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $4.4b. 14% off the 52-week high of $42.81. Revenue growing +13%, comfortably above the S&P median. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $49.00 (implying +33% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$111m) — capital raises or debt issuance likely required; dilution / leverage risk. ROE -171% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $15.5b. 18% off the 52-week high of $186.12. Revenue growing +34% — in hypergrowth territory. PEG 0.46 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $211.57 (implying +39% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where INDV and NBIX diverge
On the headline score the gap is 25.0 points in favor of NBIX. The widest single difference is Quality, where NBIX leads by 31.2 points.
- QualityINDV 49.9 · NBIX 81.1NBIX +31.2
- ValueINDV 57.5 · NBIX 87.7NBIX +30.2
- GrowthINDV 87.2 · NBIX 95.9NBIX +8.7
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.